Abstract
Bristol Myers Squibb's acquisition of Mirati Therapeutics is poised to strengthen the former's position in the targeted therapy market, not only with the KRASG12C inhibitor adagrasib but also with Mirati's other assets, including a potential first-in-class PRMT5 inhibitor.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
